

**MEDIA RELEASE**  
17 November 2006

ACN 079 253 606

E [cytopia@cytopia.com.au](mailto:cytopia@cytopia.com.au)

[www.cytopia.com.au](http://www.cytopia.com.au)



Cytopia Limited                      PO Box 6492  
Level 5                                      St Kilda Road Central  
Baker Heart Research              Melbourne Victoria 8008  
Institute Building                      Australia  
Commercial Road  
Melbourne Victoria 3004  
Australia

**Cytopia broadens cancer pipeline with new preclinical candidate**

Cytopia Limited announced today that it has broadened its anticancer drug pipeline with the selection of CYT645 as a preclinical drug development candidate. CYT645 is a potent and selective small-molecule inhibitor of c-FMS, a kinase enzyme intimately involved in both the growth and spread of cancer (metastasis). c-FMS also plays a role in many inflammatory disorders, including rheumatoid arthritis and inflammatory bowel disease.

“c-FMS is an important target for the inhibition of tumour metastasis”, said Dr Andrew Wilks, Chief Scientific Officer. “All indications are that our c-FMS programme is amongst the most advanced in the global pharmaceutical arena and as such we are well placed to progress CYT645 into the clinic as another treatment modality for solid tumours and potentially diseases such as rheumatoid arthritis”.

“Nomination of CYT645 as a development candidate follows an intensive period of endeavour by all scientific divisions of the company and is proof of the substantial internal drug discovery and development skills of Cytopia’s scientists”, said Dr Chris Burns, Research Director.

The company will now undertake a formal development programme including further animal efficacy studies; scale-up chemistry and preclinical toxicology studies leading to the filing of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) of the United States. It is anticipated that this programme will take nine to twelve months to complete.

It is intended that CYT645 will be advanced into a Phase I clinical trial during late 2007 or early 2008, subject to the successful completion of the preclinical programme and regulatory approval.

## **About Cytopia**

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer, immune disorders and cardiovascular diseases. Cytopia conducts its research and development via subsidiaries based in Melbourne and New York and specialises in discovering new molecules that can inhibit enzymes known as kinases, an exciting new class of drugs.

For more information please contact:

Mr Andrew Macdonald  
Chief Executive Officer  
T: +61 3 9522 6920  
E: [andrew.macdonald@cytopia.com.au](mailto:andrew.macdonald@cytopia.com.au)

or, visit our website at: [www.cytopia.com.au](http://www.cytopia.com.au)